Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Novel cooperative pathway of c-Myc and Furin, a pro-protein convertase, in cell proliferation as a therapeutic target in ovarian cancers.

Hasegawa-Minato J, Toyoshima M, Ishibashi M, Zhang X, Shigeta S, Grandori C, Kitatani K, Yaegashi N.

Oncotarget. 2017 Dec 15;9(3):3483-3496. doi: 10.18632/oncotarget.23322. eCollection 2018 Jan 9.

2.

Notch1 regulates tongue cancer cells proliferation, apoptosis and invasion.

Gan RH, Wei H, Xie J, Zheng DP, Luo EL, Huang XY, Xie J, Zhao Y, Ding LC, Su BH, Lin LS, Zheng DL, Lu YG.

Cell Cycle. 2018;17(2):216-224. doi: 10.1080/15384101.2017.1395534. Epub 2017 Dec 21.

PMID:
29117785
3.

Notch and its oncogenic activity in human malignancies.

Brzozowa-Zasada M, Piecuch A, Michalski M, Segiet O, Kurek J, Harabin-Słowińska M, Wojnicz R.

Eur Surg. 2017;49(5):199-209. doi: 10.1007/s10353-017-0491-z. Epub 2017 Sep 18. Review.

4.

The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.

Allam H, Johnson BP, Zhang M, Lu Z, Cannon MJ, Abbott KL.

J Biol Chem. 2017 Sep 29;292(39):16351-16359. doi: 10.1074/jbc.M117.783936. Epub 2017 Aug 23.

PMID:
28842505
5.

Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3.

Zou B, Wang H, Liu Y, Qi P, Lei T, Sun M, Wang Y.

Oncol Rep. 2017 Sep;38(3):1431-1441. doi: 10.3892/or.2017.5814. Epub 2017 Jul 13.

6.

Prognostic roles of Notch receptor mRNA expression in human ovarian cancer.

Chen C, Wang X, Huang S, Wang L, Han L, Yu S.

Oncotarget. 2017 May 16;8(20):32731-32740. doi: 10.18632/oncotarget.16387.

7.

The role of Notch signaling in the mammalian ovary.

Vanorny DA, Mayo KE.

Reproduction. 2017 Jun;153(6):R187-R204. doi: 10.1530/REP-16-0689. Epub 2017 Mar 10. Review.

8.

Using knowledge-driven genomic interactions for multi-omics data analysis: metadimensional models for predicting clinical outcomes in ovarian carcinoma.

Kim D, Li R, Lucas A, Verma SS, Dudek SM, Ritchie MD.

J Am Med Inform Assoc. 2017 May 1;24(3):577-587. doi: 10.1093/jamia/ocw165.

9.

Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer.

Feng Z, Xu W, Zhang C, Liu M, Wen H.

Oncotarget. 2017 Jan 31;8(5):8215-8225. doi: 10.18632/oncotarget.14152.

10.

Efficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome.

Zhao YC, Zhang L, Feng SS, Hong L, Zheng HL, Chen LL, Zheng XL, Ye YQ, Zhao MD, Wang WX, Zheng CH.

Int J Nanomedicine. 2016 Oct 20;11:5485-5496. eCollection 2016.

11.

Functional redundancy of the Notch pathway in ovarian cancer cell lines.

Silva F, Félix A, Serpa J.

Oncol Lett. 2016 Oct;12(4):2686-2691. Epub 2016 Aug 5.

12.

Notch signalling pathway as an oncogenic factor involved in cancer development.

Brzozowa-Zasada M, Piecuch A, Dittfeld A, Mielańczyk Ł, Michalski M, Wyrobiec G, Harabin-Słowińska M, Kurek J, Wojnicz R.

Contemp Oncol (Pozn). 2016;20(4):267-72. doi: 10.5114/wo.2016.61845. Epub 2016 Sep 5. Review.

13.

Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain.

Kang HG, Kim DH, Kim SJ, Cho Y, Jung J, Jang W, Chun KH.

Oncotarget. 2016 Oct 18;7(42):68229-68241. doi: 10.18632/oncotarget.11920.

14.

Metastasis-associated lung adenocarcinoma transcript 1 promotes the proliferation of chondrosarcoma cell via activating Notch-1 signaling pathway.

Xu F, Zhang ZQ, Fang YC, Li XL, Sun Y, Xiong CZ, Yan LQ, Wang Q.

Onco Targets Ther. 2016 Apr 13;9:2143-51. doi: 10.2147/OTT.S100003. eCollection 2016.

15.

Expression of Notch 1 receptor associated with tumor aggressiveness in papillary thyroid carcinoma.

Fu H, Ma C, Guan W, Cheng W, Feng F, Wang H.

Onco Targets Ther. 2016 Mar 15;9:1519-23. doi: 10.2147/OTT.S98239. eCollection 2016.

16.

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.

Ricci F, Fratelli M, Guffanti F, Porcu L, Spriano F, Dell'Anna T, Fruscio R, Damia G.

Oncotarget. 2017 Jan 31;8(5):7441-7451. doi: 10.18632/oncotarget.7465.

17.

3D Chromosome Regulatory Landscape of Human Pluripotent Cells.

Ji X, Dadon DB, Powell BE, Fan ZP, Borges-Rivera D, Shachar S, Weintraub AS, Hnisz D, Pegoraro G, Lee TI, Misteli T, Jaenisch R, Young RA.

Cell Stem Cell. 2016 Feb 4;18(2):262-75. doi: 10.1016/j.stem.2015.11.007. Epub 2015 Dec 10.

18.

Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways.

Gao Y, Rankin GO, Tu Y, Chen YC.

Int J Oncol. 2016 Jan;48(1):281-92. doi: 10.3892/ijo.2015.3257. Epub 2015 Nov 20.

19.

A 10-gene expression signature of Notch pathway predicts recurrence in ovarian carcinoma.

Chen F, Liu N.

Oncol Lett. 2015 Sep;10(3):1704-1708. Epub 2015 Jun 16.

20.

Notch signaling in prostate cancer: refining a therapeutic opportunity.

Su Q, Xin L.

Histol Histopathol. 2016 Feb;31(2):149-57. doi: 10.14670/HH-11-685. Epub 2015 Nov 2. Review.

Supplemental Content

Support Center